ASH 2023 | The significance of variant allele frequency in patients with SF3B1-mutated MDS
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study evaluating the significance of the variant allele frequency (VAF) of SF3B1 mutations in myelodysplastic syndromes (MDS). Patients with low VAF (less than 10%) exhibit distinct co-mutation patterns, including a higher prevalence of co-occurring TP53 mutations, and elevated risk scores. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: QualWorld, Gerson Lehrman Group, Abbvie, Blueprint Medicine, Caris Diagnostics, Guidepoint, Recordati/ EUSA Pharma, Daiichi Sankyo
Research Funding: Astellas, Amgen
Current equity holder in publicly-traded company: Abbvie
